TABLE 1.
Overall (n = 860) | HPV-Negative (n = 695)a | HPV-Positive (n = 164)a | P | |
---|---|---|---|---|
Age, median (interquartile range), y | 58 (51-68) | 58 (51-69) | 57.5 (50-64) | .19 |
Sex | ||||
Men | 549 (63.8%) | 63.0% | 67.1% | .33 |
Women | 311 (36.2%) | 37.0% | 32.9% | |
Race and ethnicity | ||||
White non-Hispanic | 315 (36.6%) | 32.7% | 53.7% | |
Black non-Hispanic | 276 (32.1%) | 33.8% | 25.0% | <.001 |
Asian non-Hispanic | 170 (19.8%) | 21.3% | 12.8% | |
Any race, Hispanic | 99 (11.5%) | 12.2% | 8.5% | |
Ever tobacco use | ||||
No | 159 (18.5%) | 16.5% | 26.8% | |
Yes | 502 (58.4%) | 58.8% | 56.1% | .004 |
Unknown | 199 (23.1%) | 24.6% | 17.1% | |
Current tobacco use | ||||
Nob | 406 (47.2%) | 44.0% | 60.4% | |
Yes | 244 (28.4%) | 30.1% | 21.3% | .001 |
Unknown | 210 (24.4%) | 25.9% | 18.3% | |
Alcohol use ever | ||||
No | 199 (23.1%) | 21.4% | 29.9% | |
Yes | 440 (51.2%) | 51.7% | 49.4% | .05 |
Unknown | 221 (25.7%) | 26.9% | 20.7% | |
Current alcohol use | ||||
No | 324 (37.7%) | 37.3% | 39.0% | |
Yes | 311 (36.2%) | 35.4% | 39.6% | .27 |
Unknown | 225 (26.2%) | 27.3% | 21.3% | |
Tumor stage | ||||
T1 | 217 (25.2%) | 23.6% | 32.3% | |
T2 | 220 (25.6%) | 23.2% | 36.0% | |
T3 | 154 (17.9%) | 19.4% | 11.6% | <.001 |
T4 | 222 (25.8%) | 27.8% | 17.1% | |
Indeterminate/unknown | 47 (5.5%) | 6.0% | 3.0% | |
Nodal stage | ||||
N0 | 331 (38.5%) | 44.3% | 14.0% | |
N1, N2a, N2b | 342 (39.8%) | 33.8% | 64.6% | <.001 |
N2c, N3 | 131 (15.2%) | 14.8% | 17.1% | |
Indeterminate/unknown | 56 (6.5%) | 7.1% | 4.3% | |
Anatomic site | ||||
Oropharynx | 239 (27.8%) | 15.1% | 81.7% | |
Oral cavity | 253 (29.4%) | 35.7% | 3.0% | <.001 |
Nasopharynx | 125 (14.5%) | 16.0% | 7.9% | |
Larynx | 243 (28.3%) | 33.2% | 7.3% | |
Study site | ||||
Johns Hopkins Hospital | 434 (50.5%) | 49.1% | 56.1% | .11 |
University of California San Francisco | 426 (49.5%) | 50.9% | 43.9% | |
Vital status | ||||
Death due to any cause | 444 (51.6%) | 56.4% | 31.1% | <.001 |
Death due to HNSCCc | 185 (25.0%) | 27.8% | 13.0% | <.001 |
Second primary | ||||
No | 681 (79.2%) | 79.1% | 79.3% | |
Yes | 49 (5.7%) | 5.8% | 5.5% | .99 |
Unknown | 130 (15.1%) | 15.1% | 15.2% | |
Recurrence | ||||
No | 536 (62.3%) | 60.0% | 72.6% | |
Persistent disease | 70 (8.1%) | 8.8% | 5.5% | |
No treatment | 31 (3.6%) | 3.7% | 3.0% | .02 |
Yes | 159 (18.5%) | 20.1% | 11.0% | |
Unknown | 64 (7.4%) | 7.3% | 7.9% |
Abbreviations: HNSCC, head and neck squamous cell cancer; HPV, human papillomavirus.
Any high-risk HPV infection as determined by the in situ hybridization test detailed in the Materials and Methods section. Note that 1 participant did not have HPV ISH results and was therefore excluded from the stratified columns of this table.
This includes former and never smokers.
One hundred nineteen patients with an unknown cause of death were excluded.